Fondation Ophtalmologique A. de Rothschild
Paris, France, 75019
NCT Number: NCT03268239
Gadolinium-enhanced magnetic resonance imaging (MRI) is currently the imaging gold standard to detect active inflammatory lesions in multiple sclerosis (MS) patients. The sensitivity of enhanced MRI to detect active lesions may vary according to the acquisition strategy used (e.g., delay between injection and image acquisition, contrast dose, field strength, and frequency of MRI sampling). Selection of the most appropriate T1-weighted sequence after contrast injection may also influence sensitivity. Several clinical studies performed at 1.5 Tesla have shown that conventional 2D spin-echo (SE) sequences perform better than gradient recalled-echo (GRE) sequences for depicting active MS lesions after gadolinium injection. As relates to MS, 3.0 Tesla systems offer some advantages over lower field strengths, such as higher detection rates for T2 and gadolinium-enhancing brain lesions, an important capability for diagnosing and monitoring MS patients. Recent studies have shown that at 3 Tesla, 3D GRE or 3D fast SE sequences provide higher detection rates for gadolinium-enhancing MS lesions, especially smaller ones, than standard 2D SE, and better suppress artefacts related to vascular pulsation. However, the comparison of the performance of 3D GRE versus 3D SE sequences has not been investigated yet.
Objectives To compare the sensitivity of enhancing multiple sclerosis (MS) lesions in gadolinium-enhanced 3D T1-weighted gradient-echo (GRE) and turbo-spin-echo (TSE) sequences.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, France, 75019
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Due to the participation in the study, the following sequences are added to the imaging protocol:
Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition.
Time frame: Baseline
Number of gadolinium-enhanced brain lesions depicted on a 3D T1 Turbo Spin Echo sequence compared to those depicted on the 3D T1 Gradient-Recalled Echo sequence.
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: COGITE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03268096
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsNCT07330687
Brain, Cleft Lip and/or Palate
Wenzhou, Zhejiang, China
View Trial DetailsNCT04979650
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Sari, Mazandaran, Iran
View Trial DetailsNCT01517087
Central Nervous System, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details